A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

 

 

Authors: David R. Boulware, M.D., M.P.H., Matthew F. Pullen, M.D., Ananta S. Bangdiwala, M.S., Katelyn A. Pastick, B.Sc., Sarah M. Lofgren, M.D., Elizabeth C. Okafor, B.Sc., Caleb P. Skipper, M.D., Alanna A. Nascene, B.A., Melanie R. Nicol, Pharm.D., Ph.D., Mahsa Abassi, D.O., M.P.H., Nicole W. Engen, M.S., Matthew P. Cheng, M.D., et al.

 

BACKGROUND

Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown.

 

To continue reading the full article please follow the link: https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?query=featured_home 

 PDF version: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2016638?articleTools=true